Business Context and Reporting Period
Company: DAXOR CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1996
Business Overview: Daxor operates laboratories (Idant Laboratories) and holds a significant portfolio of marketable securities. The company also markets a Blood Volume Analyzer (BVA-100) and recently incorporated a subsidiary, Daxor Health Services, Inc., in Florida.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Total Revenues | $635,996 | $1,246,502 |
| Operating Revenues | $177,676 | $503,480 |
| Net Income (Loss) | $(111,795) | $569,982 |
| Net Income Per Share | $(0.02) | $0.11 |
| Cash and Equivalents (End of Period) | $200,654 | $44,284 |
| Marketable Securities (Fair Value) | $33,588,246 | $35,735,073 |
| Total Assets | $35,256,772 | $37,744,621 |
| Loans Payable | $318,997 | $1,536,609 |
Note: The filing does not provide explicit margin percentages; however, the company reported a net loss for the quarter.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 49% year-over-year, driven primarily by a 65% drop in operating revenues.
- Profitability Reversal: The company shifted from a net income of $569,982 in Q1 1995 to a net loss of $111,795 in Q1 1996.
- Debt Reduction: Loans payable decreased significantly from $1,536,609 to $318,997, reflecting a $900,000 repayment of a bank loan during the quarter.
- Cash Flow: Net cash provided by operating activities was $290,742, compared to a net cash use of $20,162 in the prior year period.
- Investment Portfolio: Unrealized gains on available-for-sale securities decreased slightly, with the portfolio value dropping from $35.7 million to $33.6 million.
Outlook, Risks, and Management Commentary
- License Restoration: Operating revenues fell sharply after the New York State Department of Health revoked licenses for Idant Laboratories on August 21, 1995. On May 16, 1996, the Appellate Court ordered the restoration of all licenses in a 5-0 decision. Management expects revenues to return to previous levels as operations resume.
- Future Growth: Significant additional revenue is anticipated upon approval of the blood volume analyzer and its isotope for medical use.
- New Subsidiary: The company has begun receiving revenues from Daxor Health Services, Inc., a Florida subsidiary incorporated in January 1996.
- Liquidity: Management states the company has adequate resources to sustain its blood bank and develop the BVA-100 instrument. However, expanding blood banking operations on a nationwide basis would require additional capital.
- Risks: The company relies heavily on investment income (dividends and gains) to offset operating losses during the period of restricted laboratory operations.
Investor Verification Checklist
- Confirm the operational status of Idant Laboratories following the May 16, 1996 court order restoring licenses.
- Verify the regulatory approval timeline for the Blood Volume Analyzer (BVA-100) and its associated isotope.
- Assess the sustainability of dividend income from the $33.6 million marketable securities portfolio as a primary revenue source.
- Review the capital requirements for the planned nationwide expansion of blood banking operations.
- Monitor the performance of the new Daxor Health Services, Inc. subsidiary in Florida.